Platform trial designs in drug development : umbrella trials and basket trials
著者
書誌事項
Platform trial designs in drug development : umbrella trials and basket trials
(Chapman & Hall/CRC biostatistics series)(A Chapman & Hall book)
CRC Press, c2019
- : hardback
大学図書館所蔵 全4件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Includes bibliographical references and index
内容説明・目次
内容説明
Platform trials test multiple therapies in one indication, one therapy for multiple indications, or both. These novel clinical trial designs can dramatically increase the cost-effectiveness of drug development, leading to life-altering medicines for people suffering from serious illnesses, possibly at lower cost. Currently, the cost of drug development is unsustainable. Furthermore, there are particular problems in rare diseases and small biomarker defined subsets in oncology, where the required sample sizes for traditional clinical trial designs may not be feasible.
The editors recruited the key innovators in this domain. The 20 articles discuss trial designs from perspectives as diverse as quantum computing, patient's rights to information, and international health.
The book begins with an overview of platform trials from multiple perspectives. It then describes impacts of platform trials on the pharmaceutical industry's key stakeholders: patients, regulators, and payers. Next it provides advanced statistical methods that address multiple aspects of platform trials, before concluding with a pharmaceutical executive's perspective on platform trials. Except for the statistical methods section, only a basic qualitative knowledge of clinical trials is needed to appreciate the important concepts and novel ideas presented.
目次
I. Overview of Platform Clinical Trials
Introduction
Robert A. Beckman and Zoran Antonijevic
I-SPY2: Unlocking the potential of the platform trial
Laura Esserman, Nola Hylton, Smita Asare, Christina Yau, Doug Yee, Angie Demichele, Jane Perlmutter, Fraser Symmans, Laura van't Veer, Jeff Matthews, Don Berry, and Anna Barker
The challenges with Multi-arm targeted therapy trials
Ryan J. Sullivan and Keith Flaherty.
Basket trials at the confirmatory stage
Robert A. Beckman and Cong Chen
Harnessing Real World Data to Inform Platform Trial Design
Daphne A. Guinn, Subha Madhavan, and Robert A. Beckman
Impact of Platform Trials on Pharmaceutical Frameworks
Zoran Antonijevic, Edward Mills, Jonas Haggstroem, and Kristian Thorlund.
II. Stakeholders
Friends of Cancer Research Perspective on Platform trials
Jeff D. Allen, Madison Wempe, Ryan Hohman, and Ellen Sigal
Regulatory and Policy aspects of Platform trials
Rasika Kalamegham, Ramzi Dagher, and Peter Honig
Multi-arm, multi-drug trials from a reimbursement perspective
Anja Schiel, and Olivier Collignon
Highly Efficient Clinical Trials: A resource-saving solution for global health
Edward Mills, Jonas Haggstroem, and Kristian Thorlund.
Decision Analysis from the Perspectives of Single and Multiple Stakeholders
Robert A. Beckman, Carl-Fredrik Burman, Cong Chen, Sebastian Jobjoernsson, Franz Koenig, Nigel Stallard, and Martin Posch.
Optimal Approach for Addressing Multiple Stakeholders' Requirements in Drug Development
Zoran Antonijevic and Zhongshen Wang
III. Statistical Methodology
Primary Site Independent Clinical Trials in Oncology
Richard M. Simon
Platform Trials
Ben Saville and Scott Berry
Efficiencies of Platform TrialsSatrajit Roychoudhury and Ohad Amit.
Control of Type I Error for Confirmatory Basket trials
Cong Chen and Robert A. Beckman
Benefit-Risk Assessment for Platform Trials
Chunlei Ke and Qi Jiang
Effect of Randomization Schemes in Umbrella Trials when There Are Unknown Interactions between Biomarkers
Janet LI, Shuai Yuan, and Robert A. Beckman
Combinatorial and model-based methods in structuring and optimizing cluster trials
Valerii Fedorov and Sergei Leonov
IV. Conclusions
An executive's view of value of platform trials
David Reese and Phuong K Morrow
「Nielsen BookData」 より